News

Contact:
Herborium Group, Inc.
Dr. Agnes Olszewski, CEO
201 647 3757

FOR IMMEDIATE RELEASE

HERBORIUM GROUP, INC enters acne treatment market in the UK with the introduction and commencement of sales of AcnEase®, its proprietary, novel, herbal acne treatment. Tuesday, May 19, 2009

Saddle Brook, NJ--(BUSINESS WIRE)--Herborium Group, Inc, (HBRM), a botanical therapeutics® company that develops, licenses and markets novel, botanical ingredient based medicinal products, today announced that it has entered into a long-term distribution Agreement with the largest retailer of male grooming products in the UK, Mankind LLC. In addition to its leading market share of the male grooming market, Mankind also commands a sizeable market share of the UK Internet female cosmetic market.

“We are very excited about the potential for AcnEase®, our novel, herbal acne treatment, in the UK.” said Dr. Agnes P. Olszewski, CEO of Herborium Group. “The Dermatology Market Outlook for 2011 forecasts that, collectively, the acne market is estimated to be $2.7 billion in 2011. The major dermatological indications included in this market are acne, the largest segment, and Rosacea the fifth largest segment, both of which are treated successfully by AcnEase. In clinical studies AcnEase® has demonstrated up to 95% efficacy in diminishing acne and improving skin condition. The market for natural based products in the UK is estimated to be over $25 billion. Sales of AcnEase® in the UK have commenced and we expect steady growth in 2009 and beyond, since our product fits the growing market need for all natural and safe products, as well as the high demand for acne (dermatologic) treatments.”

Herborium editorial on Acne Treatment has been selected for publication by NATIONAL ASSOCIATION of PRIMARY CARE REVIEW – Summer 2009, a leading journal targeting General Practitioners and the GP Trusts in the UK.

For more information about Herborium and AcnEase visit the following links:
www.herborium.com and www.acnease.com

About Herborium Group, Inc.

Herborium Group, Inc., a botanical therapeutics® company, is focused on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and health care professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to Western markets. The company has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women’s Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.

Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Sunrise Consulting Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.